Logo image of HLVX

HILLEVAX INC (HLVX) Stock Price, Quote, News and Overview

NASDAQ:HLVX - Nasdaq - US43157M1027 - Common Stock - Currency: USD

1.85  0 (0%)

After market: 1.85 0 (0%)

HLVX Quote, Performance and Key Statistics

HILLEVAX INC

NASDAQ:HLVX (4/25/2025, 8:13:15 PM)

After market: 1.85 0 (0%)

1.85

0 (0%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High16.31
52 Week Low1.34
Market Cap92.76M
Shares50.14M
Float30.21M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO04-29 2022-04-29


HLVX short term performance overview.The bars show the price performance of HLVX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10 15

HLVX long term performance overview.The bars show the price performance of HLVX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of HLVX is 1.85 USD. In the past month the price increased by 14.91%. In the past year, price decreased by -85.54%.

HILLEVAX INC / HLVX Daily stock chart

HLVX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.12 329.14B
AMGN AMGEN INC 14.17 150.99B
GILD GILEAD SCIENCES INC 13.33 128.61B
VRTX VERTEX PHARMACEUTICALS INC 1702.9 126.96B
REGN REGENERON PHARMACEUTICALS 13.2 65.88B
ARGX ARGENX SE - ADR 323.56 37.54B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.72B
ONC BEIGENE LTD-ADR N/A 26.39B
BNTX BIONTECH SE-ADR N/A 24.52B
NTRA NATERA INC N/A 20.79B
BIIB BIOGEN INC 7.22 17.39B
SMMT SUMMIT THERAPEUTICS INC N/A 17.30B

About HLVX

Company Profile

HLVX logo image HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. The company is headquartered in Boston, Massachusetts and currently employs 14 full-time employees. The company went IPO on 2022-04-29. The firm's programs, HIL-214 and HIL-216, are virus-like particle (VLP) based vaccine candidates in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HIL-214 consists of VLPs which are designed to mimic the structure of norovirus and are co-formulated with an alum adjuvant to enhance immunogenicity and stability of the VLPs in solution. HIL-214 is administered intramuscularly via prefilled syringes and has demonstrated stability at standard refrigeration temperatures of four degrees Celsius for 24 months. The firm has in-licensed HIL-216 from Chengdu Kanghua Biological Products Co., Ltd. (Kangh), a Chinese company. Its license provides world-wide rights to the vaccine outside of the Chinese market. HIL-216 includes six common norovirus genotypes: GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.

Company Info

HILLEVAX INC

321 Harrison Ave, Suite 500

Boston MASSACHUSETTS US

Employees: 90

Company Website: https://www.hillevax.com/

Investor Relations: https://ir.hillevax.com/

Phone: 16172135054

HILLEVAX INC / HLVX FAQ

What is the stock price of HILLEVAX INC today?

The current stock price of HLVX is 1.85 USD.


What is the ticker symbol for HILLEVAX INC stock?

The exchange symbol of HILLEVAX INC is HLVX and it is listed on the Nasdaq exchange.


On which exchange is HLVX stock listed?

HLVX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for HILLEVAX INC stock?

8 analysts have analysed HLVX and the average price target is 2.04 USD. This implies a price increase of 10.27% is expected in the next year compared to the current price of 1.85. Check the HILLEVAX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is HILLEVAX INC worth?

HILLEVAX INC (HLVX) has a market capitalization of 92.76M USD. This makes HLVX a Micro Cap stock.


How many employees does HILLEVAX INC have?

HILLEVAX INC (HLVX) currently has 90 employees.


What are the support and resistance levels for HILLEVAX INC (HLVX) stock?

HILLEVAX INC (HLVX) has a support level at 1.64 and a resistance level at 1.87. Check the full technical report for a detailed analysis of HLVX support and resistance levels.


Should I buy HILLEVAX INC (HLVX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does HILLEVAX INC (HLVX) stock pay dividends?

HLVX does not pay a dividend.


What is the Price/Earnings (PE) ratio of HILLEVAX INC (HLVX)?

HILLEVAX INC (HLVX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3).


What is the Short Interest ratio of HILLEVAX INC (HLVX) stock?

The outstanding short interest for HILLEVAX INC (HLVX) is 5.27% of its float. Check the ownership tab for more information on the HLVX short interest.


HLVX Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to HLVX. When comparing the yearly performance of all stocks, HLVX is a bad performer in the overall market: 91.46% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

HLVX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to HLVX. No worries on liquidiy or solvency for HLVX as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

HLVX Financial Highlights

Over the last trailing twelve months HLVX reported a non-GAAP Earnings per Share(EPS) of -3. The EPS increased by 1.32% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -76.43%
ROE -95.33%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%12.82%
Sales Q2Q%N/A
EPS 1Y (TTM)1.32%
Revenue 1Y (TTM)N/A

HLVX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 48% to HLVX. The Buy consensus is the average rating of analysts ratings from 8 analysts.


Ownership
Inst Owners54.36%
Ins Owners2.24%
Short Float %5.27%
Short Ratio7.76
Analysts
Analysts47.5
Price Target2.04 (10.27%)
EPS Next Y53.76%
Revenue Next YearN/A